1 Add-on maintenance in patients with inadequate response to nasal steroids. 2 Add-on maintenance of chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with inadequate response to nasal ...

The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Surgery precedes biologics but comes after saline irrigations and topical intranasal corticosteroids in a new treatment algorithm for US clinicians treating patients who have chronic rhinosinusitis ...

A new add-on therapy administered every six months targets key inflammatory pathways in asthma and chronic rhinosinusitis ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is the first treatment in the U.S. for CRSwNP for adolescents. The approval is supported by data from ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways. Dupilumab has been approved for a range of other conditions including chronic ...

Nasal polyps are painless, teardrop-shaped growths that form in your nose or sinuses. They’re most common where the sinuses near your eyes and cheekbones drain into your nose. Nasal polyps are not ...

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...